Phylogica Limited

ASX:PYC ISIN:AU000000PYC7

Phylogica Limited (Phylogica) is an Australia-based company principally engaged in the discovery and development of therapeutics directed at proteins and their interactions. The Company is engaged in the discovery of peptide-based drugs to treat inflammatory diseases.  
 
        

查看其它語言版本

新聞

2010年12月20日澳洲股市:IMX Resources (ASX:IXR)首批鐵銅礦石船運貨物發往中國

🕔12/20/2010 1:30:00 PM 12060

2010年12月20日澳洲股市:IMX Resources (ASX:IXR)已向中國發運第一批鐵銅礦石貨物;澳洲藥品開發公司Phylogica Limited (ASX:PYC)已與輝瑞製藥(NYSE:PFE)簽訂合作與許可證協議;Copper Strike Limited (ASX:CSE)在昆士蘭西北部的Walford Creek項目已取得良好的銅/銀/鈷結果;South American Ferro Metals Limited (ASX:SFZ)在巴西生產的鐵礦石超出400,000噸。

閱讀全文
###

87,208 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 29) (過去30日: 111) (自發布以來: 9610) 

公司詳細

    傳真
  • 08 9423 8899 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.phylogica.com/

更多新聞紀錄

  • 2024/12/16: PYC Nominates Fourth Clinical Drug Candidate in PMS Program*
  • 2024/11/28: Polycystic Kidney Disease Program Investor Presentation*
  • 2024/11/27: Notification of cessation of securities - PYC*
  • 2024/11/27: Notification regarding unquoted securities - PYC*
  • 2024/11/27: Change of Director's Interest Notice*
  • 2024/11/27: PYC to Progress Kidney Drug Candidate Into Human Trials*
  • 2024/11/22: Presentation of RP11 Clinical Trial Data at APVRS 2024*
  • 2024/11/21: Completion of Share Consolidation*
  • 2024/11/14: Share Consolidation and ASX Code*
  • 2024/11/13: Update - Consolidation/Split - PYC*
*refer to company website